ImmunoCellular (OTC BB IMUC) receives Notice of Allowance of Patent

Home > ImmunoCellular Therapeutics, IMUC.OB, Patent Issuance > ImmunoCellular (OTC BB IMUC) receives Notice of Allowance of Patent

ImmunoCellular (OTC BB IMUC) receives Notice of Allowance of Patent

October 10th, 2011 Henry McCusker Leave a comment Go to comments

For key US Patent for Lead Product Candidate, ICT-107.

OTCBB: IMUC received allowance of patent claims related to ICT-107, the dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM); titled “Cancer Vaccines and Vaccination Methods,” which covers the method of delivery and the composition of the six antigens in ICT-107 that include TRP-2, MAGE-1, HER-2,IL-13 receptor a2, gp100 and AIM-2.

The Bottom Line: The notice of allowance for this patent provides support for intellectual property protection.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.